Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 27, 2011
Wed, January 26, 2011 MYGN, MRNA, MNTA, MNKD, MDVN, MDCO, Biomed - Genetics Stocks 10.27% undervalued
January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. MYRIAD GENETICS INC (NASDAQ:MYGN), MARINA CAPITAL INC (NASDAQ:MRNA), MOMENTA PHARMACEUTICALS INC (NASDAQ:MNTA), MANNKIND CORP (NASDAQ:MNKD), MEDIVATION INC (NASDAQ:MDVN), MEDICINES COMPANY (NASDAQ:MDCO) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.
The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:
Symbol Company Name Last Close Fair Value Valuation Industry
MYGN MYRIAD GENETICS INC 21.54 24.01 10.27% undervalued Biomed - Genetics
MRNA MARINA CAPITAL INC 1.12 4.48 75.00% undervalued Biomed - Genetics
MNTA MOMENTA PHARMACEUTICALS INC 12.5 22.83 45.25% undervalued Biomed - Genetics
MNKD MANNKIND CORP 5.4075 9.99 45.86% undervalued Biomed - Genetics
MDVN MEDIVATION INC 14.52 19.77 26.55% undervalued Biomed - Genetics
MDCO MEDICINES COMPANY 15.93 18.96 15.98% undervalued Biomed - Genetics
Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.
Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.
MYRIAD GENETICS INC (NASDAQ:MYGN) - Myriad Genetics, Inc., a healthcare company, focuses on the development and marketing of novel molecular diagnostic products. It commercializes predictive medicine, personalized medicine, and prognostic medicine products. The company markets BRACAnalys for assessing a womans risk for breast and ovarian cancer; COLARIS molecular for assessing a persons risk of developing colorectal cancer or uterine cancer; COLARIS AP, a molecular diagnostic product for colon cancer that detects mutations in the APC and MYH genes; and MELARIS, which assesses a persons risk of developing melanoma. It also offers OnDose, a personalized medicine product to measure a patient's exposure to 5-FU chemotherapy; PREZEON that assesses loss of PTEN function in cancer patients; and TheraGuide 5-FU assesses a person's risk of developing a toxic reaction to 5-FU-based chemotherapy. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MARINA CAPITAL INC (NASDAQ:MRNA) - MARINA CAPITAL INC
MOMENTA PHARMACEUTICALS INC (NASDAQ:MNTA) - Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; M118, an anticoagulant for acute coronary syndromes; and M402, a novel HSPG-based product candidate. Momenta Pharmaceuticals has collaboration agreements with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts.
MANNKIND CORP (NASDAQ:MNKD) - MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA, a rapid-acting insulin that has completed Phase III clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company is also preparing to initiate a Phase II study of MKC1106-MT in patients with advanced melanoma. Its products also include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; and MKC1106-PP, a Phase I clinical trials product for the treatment of diverse tumor types, metastatic diseases, and/or progressive, refractory disease. In addition, the company conducts preclinical studies of drug candidates, MKC204, which may have the potential to treat certain malignancies and inflammatory diseases; MKC180, an obesity compound; and MKC1106-NS, a cancer immunotherapy product. MannKind Corporation was founded in 1991 and is based in Valencia, California.
MEDIVATION INC (NASDAQ:MDVN) - Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimers disease, Huntington disease, and castration-resistant prostate cancer. The companys product candidates under clinical development include Dimebon, which is in Phase III clinical trial for the treatment of Alzheimers disease and Huntington disease; and MDV3100, which is in Phase III clinical trial for the treatment of castration-resistant prostate cancer. It has collaboration agreements with Pfizer Inc to develop and commercialize Dimebon; and Astellas Pharma Inc. to develop and commercialize MDV3100. The company was founded in 2003 and is based in San Francisco, California.
MEDICINES COMPANY (NASDAQ:MDCO) - The Medicines Company operates as a global pharmaceutical company with a focus on advancing the treatment of critical care patients. The company markets Angiomax for use in patients undergoing coronary angioplasty; and Cleviprex, an injectable emulsion for the reduction of blood pressure. Its developing products include Cangrelor, an antiplatelet agent, which is in phase III clinical trial for the prevention of platelet activation and aggregation; Oritavancin that is in phase III clinical trial acts as an antibiotic for the treatment of serious gram-positive bacterial infections, including ABSSSI; and Argatroban, a phase III and NDA filed direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis. The Medicines Companys developing products also include CU2010, which is in phase I clinical trial that acts as a serine protease inhibitor for the reduction of blood loss during surgery; and ApoA-I Milano, a phase I clinical trial product for the reversal of atherosclerotic plaque development and reduction of the risk of coronary events in patients with ACS. The company sells its products through sales representatives and managers. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
Contact:
BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net
- WOPRAI
- support@woprai.com